TMAO metaorganismal pathway and chronic inflammatory diseases
Exploration of Medicine · 23.06.2025 · 6
DOI: 10.37349/emed.2025.1001339 ↗Kurz gefasst
Fachartikel in der Zeitschrift Exploration of Medicine, online erschienen am 23.06.2025. Verfasst von Zeneng Wang und 2 weiteren Autor:innen. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 175 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Nutrients containing a trimethylamine (TMA) moiety in their structure can be metabolized by the gut microbiota through enzymatic cleavage of the C-N bond, producing TMA. In the liver, TMA is subsequently oxidized to trimethylamine N-oxide (TMAO) by flavin monooxygenases (FMOs). TMAO exerts pro-atherogenic and pro-inflammatory effects that contribute mechanistically to several chronic inflammatory diseases including cardiovascular disease, chronic kidney disease, obesity, non-alcoholic fatty liver disease, and neurodegenerative diseases. Targeting this metaorganismal pathway may offer substantial health benefits in the prevention and treatment of chronic inflammatory conditions.
Zitieren
APA
Wang, Z., Man, S., & Koeth, R. (2025). TMAO metaorganismal pathway and chronic inflammatory diseases. Exploration of Medicine, 6. https://doi.org/10.37349/emed.2025.1001339
Vancouver
Wang Z, Man S, Koeth R. TMAO metaorganismal pathway and chronic inflammatory diseases. Exploration of Medicine. 2025;6. doi:10.37349/emed.2025.1001339
BibTeX
@article{Wang2025,
author = {Wang, Zeneng and Man, Shumei and Koeth, Robert},
title = {TMAO metaorganismal pathway and chronic inflammatory diseases},
journal = {Exploration of Medicine},
year = {2025},
volume = {6},
doi = {10.37349/emed.2025.1001339}
}
EUVIMED